TY - JOUR
T1 - Inherited risk of dementia and the progression of cerebral small vessel disease and inflammatory markers in cognitively healthy midlife adults
T2 - the PREVENT-Dementia study
AU - Low, Audrey
AU - Su, Li
AU - Stefaniak, James D
AU - Mak, Elijah
AU - Dounavi, Maria-Eleni
AU - Muniz-Terrera, Graciela
AU - Ritchie, Karen
AU - Ritchie, Craig W
AU - Markus, Hugh S
AU - O'Brien, John T
N1 - Funding Information:
The authors thank all the PREVENT-Dementia participants for their enthusiastic participation in this study, the radiographers at the Clinical Imaging Facility, Imperial College London for their technical expertise and support in data acquisition, and the West London Mental Health National Health Service (NHS) Trust (now known as West London NHS Trust) for their help in subject recruitment. Funding: Research grants from the UK Alzheimer's Society, the US Alzheimer's Association and philanthropic donations. This work was funded by a grant for the PREVENT-Dementia program from the UK Alzheimer's Society (grant numbers 178 and 264), and the PREVENT-Dementia study is also supported by the US Alzheimer's Association (grant number TriBEKa-17?519007) and philanthropic donations. AL is supported by the Lee Kuan Yew Fitzwilliam PhD Scholarship and the Tan Kah Kee Postgraduate Scholarship. EM is supported by Alzheimer's Society Junior Research Fellowship (RG 9611). JDS is a Wellcome clinical PhD fellow funded on grant 203914/Z/16/Z to the Universities of Manchester, Leeds, Newcastle and Sheffield. LS is supported by the Cambridge NIHR Biomedical Research Center (BRC) and Alzheimer's Research UK (ARUK-SRF2017B-1). HSM is supported by an NIHR Senior Investigator award. JOB and HSM receive infrastructural support from the Cambridge NIHR BRC.
Funding Information:
Funding: Research grants from the UK Alzheimer's Society, the US Alzheimer's Association and philanthropic donations. This work was funded by a grant for the PREVENT-Dementia program from the UK Alzheimer's Society (grant numbers 178 and 264 ), and the PREVENT-Dementia study is also supported by the US Alzheimer's Association (grant number TriBEKa-17–519007 ) and philanthropic donations. AL is supported by the Lee Kuan Yew Fitzwilliam PhD Scholarship and the Tan Kah Kee Postgraduate Scholarship. EM is supported by Alzheimer's Society Junior Research Fellowship ( RG 9611 ). JDS is a Wellcome clinical PhD fellow funded on grant 203914/Z/16/Z to the Universities of Manchester, Leeds, Newcastle and Sheffield. LS is supported by the Cambridge NIHR Biomedical Research Center (BRC) and Alzheimer's Research UK (ARUK-SRF2017B-1). HSM is supported by an NIHR Senior Investigator award. JOB and HSM receive infrastructural support from the Cambridge NIHR BRC.
Publisher Copyright:
© 2020 The Authors
PY - 2021/2
Y1 - 2021/2
N2 - Cerebral small vessel disease (SVD) and inflammation are increasingly recognized as key contributors to Alzheimer's disease (AD), although the timing, trajectory, and relation between them early in the disease process is unclear. Therefore, to investigate very early-stage changes, we compared 158 healthy midlife adults with and without inherited AD predisposition (APOE4 carriership (38% positive), parental family history (FH) of dementia (54% positive)) on markers of SVD (white matter hyperintensities (WMH), cerebral microbleeds), and inflammation (C-reactive protein (CRP), fibrinogen), cross-sectionally and longitudinally over two years. While WMH severity was comparable between groups at baseline, longitudinal progression of WMH was greater in at-risk groups (APOE4+ and FH+). Topographically, APOE4 was associated exclusively with deep, but not periventricular, WMH progression after adjusting for FH. Conversely, APOE4 carriers displayed lower CRP levels than noncarriers, but not fibrinogen. Furthermore, interaction analysis showed that FH moderated the effect of SVD and inflammation on reaction time, an early feature of SVD, but not episodic memory or executive function. Findings suggest that vascular and inflammatory changes could occur decades before dementia onset, and may be of relevance in predicting incipient clinical progression.
AB - Cerebral small vessel disease (SVD) and inflammation are increasingly recognized as key contributors to Alzheimer's disease (AD), although the timing, trajectory, and relation between them early in the disease process is unclear. Therefore, to investigate very early-stage changes, we compared 158 healthy midlife adults with and without inherited AD predisposition (APOE4 carriership (38% positive), parental family history (FH) of dementia (54% positive)) on markers of SVD (white matter hyperintensities (WMH), cerebral microbleeds), and inflammation (C-reactive protein (CRP), fibrinogen), cross-sectionally and longitudinally over two years. While WMH severity was comparable between groups at baseline, longitudinal progression of WMH was greater in at-risk groups (APOE4+ and FH+). Topographically, APOE4 was associated exclusively with deep, but not periventricular, WMH progression after adjusting for FH. Conversely, APOE4 carriers displayed lower CRP levels than noncarriers, but not fibrinogen. Furthermore, interaction analysis showed that FH moderated the effect of SVD and inflammation on reaction time, an early feature of SVD, but not episodic memory or executive function. Findings suggest that vascular and inflammatory changes could occur decades before dementia onset, and may be of relevance in predicting incipient clinical progression.
KW - APOE4
KW - Alzheimer's disease
KW - Cerebral microbleeds
KW - Cerebral small vessel disease
KW - Inflammation
KW - Risk factors
KW - White matter hyperintensities
U2 - 10.1016/j.neurobiolaging.2020.10.029
DO - 10.1016/j.neurobiolaging.2020.10.029
M3 - Article
C2 - 33264710
SN - 0197-4580
VL - 98
SP - 124
EP - 133
JO - Neurobiology of Aging
JF - Neurobiology of Aging
ER -